The AUA partnered with ASTRO on the guideline and it was endorsed by the SUO.
James A. Eastham, MD, explains the updates that were made in the recently released 2022 clinical practice guideline for the management of clinically localized prostate cancer from the American Urological Association (AUA) and the American Society for Radiation Oncology (ASTRO). The guideline was shared during the 2022 AUA Annual Meeting and published in the Journal of Urology (doi: 10.1097/JU.0000000000002757). The guideline was also endorsed by the Society of Urologic Oncology (SUO).
Eastham is chair of guideline development panel and chief of Urology Services at Memorial Sloan Kettering Cancer Center.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.